Modulation of oral drug bioavailability: From preclinical mechanism to therapeutic application

Cancer Investigation

Volumn 23, Issue 5, 2005, Pages 443-464

  Kuppens, Isa E L M ^a   Breedveld, P ^a   Beijnen, J H ^a,b   Schellens, J H M ^a,b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

ABC transporter; Drug absorption; Enzyme; Oral bioavailability

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ABC TRANSPORTER; ALKYLATING AGENT; ANTHRACENE DERIVATIVE; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; BIRICODAR; CHLORAMBUCIL; CYCLOSPORIN A; CYTOCHROME P450; CYTOTOXIC AGENT; DACTINOMYCIN; DAUNORUBICIN; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; DRUG METABOLIZING ENZYME; ELACRIDAR; EPIRUBICIN; ETOPOSIDE; GLYCOPROTEIN P; IRINOTECAN; LANIQUIDAR; LOPERAMIDE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 4; NAVELBINE; OC 144093; ONT 093; PACLITAXEL; TARIQUIDAR; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; ZOSUQUIDAR;

ACTIVE TRANSPORT; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DIFFUSION; DRUG FORMULATION; DRUG METABOLISM; DRUG TRANSPORT; ENDOCYTOSIS; HUMAN; LIPOPHILICITY; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; STOMACH CANCER;

EID: 24944449437     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1081/CNV-58823     Document Type: Review

References (348)

1. Akscin, J.F. The future of oral chemotherapy. In Drugs Examined at ACCC's 27th Annual National Meeting; http://www.medscape.com/ viewarticle/405930_7, (accessed January 2004).
2. Bowers, M.L.; Silberman, G.; Mortenson, L.E. Oral oncology products: barriers to successful adoption. Oncol. Issues 2002, 17, 26-27.
3. Thomas, H.; Coley, H.M. An update of the clinical strategy of inhibiting P-glycoprotein. Cancer Control 2003, 10 (2), 159-165.
4. Kakolyris, S.; Samonis, G.; Koukourakis, M.; et al. Treatment of non-small-cell lung cancer with prolonged oral etoposide. Am. J. Clin. Oncol. 1998, 21, 505-508.
5. Demario, M.D.; Ratain, M.J. Oral chemotherapy: rationale and future directions. J. Clin. Oncol. 1998, 16, 2557-2567.
6. Friedlander, M.L.; Tattersall, M.H.N. Counting costs of cancer therapy. Eur. J. Cancer Clin. Oncol. 1982, 18, 1237-1241.
7. Liu, G.; Franssen, E.; Fitch, M.I.; et al. Patients preferences for oral versus intravenous palliative chemotherapy. J. Clin. Oncol. 1997, 15, 110-115.
8. Paine, M.F.; Khalighi, M.; Fisher, J.M.; et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J. Pharmacol. Exp. Ther. 1997, 283, 1552-1562.
9. Birner, A. Safe administration of oral chemotherapy. Clin. J. Oncol. Nurs. 2003, 7 (2), 158-162.
10. Parsons, R.L. Drug absorption in gastrointestinal disease with particular reference to malabsorption syndromes. Clin. Pharmacokinet. 1977, 2 (1), 45-60.
11. Hellriegel, E.T.; Bjornsson, T.D.; Hauck, W.W. Interpatient variability in bioavailability is related to the extent of absorption: implications of bioavailability and bioequivalence studies. Clin. Pharmacol. Ther. 1996, 60, 601-607.
12. Chereson, R.; Banakar, U. Bioavailability, bioequivalence, and drug selection. In Basic Pharmacokinetics. http://pharmacy.creighton.edu/ pha443/pdf/pkin08.pdf (accessed January 2004).
13. Washington, N.; Washington, C.; Wilson, C.G. Barriers to drug absorption. In Physiological Pharmaceutics, 2nd Ed.; Taylor & Francis: London, 2001.
14. Absorption and Distribution of Drugs; Chapter 7. http://www. fleshandbones.com/readingroom/pdf/503.pdf. (accessed January 2004).
15. Macheras, P.; Reppas, C.; Dressman, J.B. Biopharmaceutics of orally administered drugs. In Pharmaceutical Technology; Ellis Horwood: London and NY, 1995.
16. Reid, G.; Wielinga, P.; Zelcer, N.; et al. Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol. Pharmacol. 2003, 63 (5), 1094-1103.
17. Drengler, R.L.; Kuhn, J.G.; Schaaf, L.J.; et al. Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors. J. Clin. Oncol. 1999, 17 (2), 685-696.
18. Shoemaker, N.E.; Kuppens, I.E.; Huinink, W.W.; Lefebvre, P.; Beijnen, J.H.; Assadourin, S.; Sanderink, G.J.; Schellens, J.H. Phase I study of an oral formulation of irinotecdan administered daily for fourteen days every three weeks in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 2005, 55 (3), 263-270.
19. Kuppens, I.L.; Bonneterre, M.-E.; Beijnen, J.H.; et al. Dose-finding phase 1 clinical and pharmacokinetic study of orally administered irinotecan (CPT-11) once daily for 14 days as single agent or in combination with capecitabine (CAP) twice daily for 14 days every 3 weeks in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. 2003, 22, 634 (abstract).
20. Berlin, J.; Benson, A.B.; Rubin, E.; et al. Phase I safety, pharmacokinetic (PK), and bioavailability (F) study of a semi-solid matrix (SSM) formulation of oral irinotecan in patients with advanced solid tumors. Am. Soc. Clin. Oncol. 2003, 22, 521 (abstract).
21. Hande, K.R.; Krozely, M.G.; Greco, F.A.; et al. Bioavailability of low-dose oral etoposide. J. Clin. Oncol. 1993, 11, 374-377.
22. Jonkman-de Vries, J.D.; Herben, V.M.M.; van Tellingen, O.; et al. Oral bioavailability of low dose (20 mg) 'home-made' etoposide capsules. Clin. Drug Investig. 1996, 6, 298-307.
23. Guo, A.; Marinaro, W.; Hu, P.; et al. Delineating the contribution of secretory transporters in the efflux of etoposide using madin-darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1) and canalicular multi-specific organic anion transporter (cMoat). Drug Metab. Dispos. 2002, 30, 457-463.
24. Wu, C.Y.; Benet, L.Z. Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine, and gg918. Drug Metab. Dispos. 2003, 11, 1292-1295.
25. Kehrer, D.F.; Soepenberg, O.; Verweij, J.; et al. Modulation of camptothecins analogs in the treatment of cancer: a review. Anti-cancer Drugs 2001, 2, 89-105.
26. Duffour, J.; Gourgou, S.; Seitz, J.F.; et al. Efficacy of propylactic anti-diarrhoeal treatment in patients receiving Campto for advanced colorectal cancer. Anticancer Res. 2002, 6B, 3727-3731.
27. Erratum in Anticancer Res. 2003, 2B, 1648.
28. Cole, S.P.C.; Bhardwaj, G.; Gerlach, J.H.; et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992, 258, 1650-1654.
29. Meerum Terwogt, J.M.; Malingré, M.M.; Beijnen, J.H.; et al. Co-administration of cyclosporin enables oral therapy with paclitaxel. Clin. Cancer Res. 1999, 5, 3379-3384.
30. Meerum Terwogt, J.M.; Beijnen, J.H.; ten Bokkel Huinink, W.W.; et al. Co-adminstration of cyclosporin A enables oral therapy with paclitaxel. Lancet 1998, 352, 185.
31. Schinkel, A.H.; Jonker, J.W. Mammalian drug efflux transporters of the ATP-binding cassette (ABC) family: an overview. Adv. Drug Deliv. Rev. 2003, 55, 3-29.
32. Bardelmeijer, H.A.; van Tellingen, O.; Schellens, J.H.M.; et al. The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery. Invest. New Drugs 2000, 18, 231-241.
33. Wielinga, P.R.; Westerhoff, H.V.; Lankelma, J. The relative importance of passive and P-glycoprotein mediated anthracycline efflux from multidrug-resistant cells. Eur. J. Biochem. 2000, 267, 649-657.
34. Zhang, X.P.; Ritke, M.K.; Yalowich, J.C.; et al. P-glycoprotein mediates profound resistance to bisantrene. Oncol. Res. 1994, 6 (7), 291-301.
35. Riley, J.; Styles, J.; Verschoyle, R.D.; et al. Association of tamoxifen billiary excretion rate with prior tamoxifen exposure and increased mdr1b expression. Biochem. Pharmacol. 2000, 60 (2), 233-239.
36. Alvarez, M.; Paull, K.; Monks, A.; et al. Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen. J. Clin. Invest. 1995, 95 (5), 2205-2214.
37. Nakagawa, M.; Schneider, E.; Dixon, K.H.; et al. Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) over-expression in mitoxantrone-resistant human MCF-7 breast cancer cells. Cancer Res. 1992, 52 (22), 6175-6181.
38. Takigawa, N.; Ohnoshi, T.; Ueoka, H.; et al. Establishment and characterization of an etoposide-resistant human small cell lung cancer cell line. Acta Med. Okayama 1992, 46 (3), 203-212.
39. Okudaira, N.; Komiya, I.; Sugiyama, Y. Polarized efflux of mono- and diacid metabolites of ME3229, an ester-type prodrug of a glycoprotein IIB/IIIa receptor antagonist, in rat small intestine. J. Pharmacol. Exp. Ther. 2000, 2, 717-723.
40. Chudhary, P.M.; Roninson, LB. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J. Natl. Cancer Inst. 1993, 85, 632-639.
41. Bergman, AM.; Pinedo, H.M.; Talianidis, L; et al. Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. Br. J. Cancer 2003, 88 (12), 1963-1970.
42. Shirakawa, K.; Takar, K.; Tanigawara, Y.; et al. Interaction of docetaxel (Taxotere) with human P-glycoprotein. Jpn. J. Cancer Res. 1999, 90, 1380-1386.
43. Jansen, W.J.; Hulscher, T.M.; van Ark-Otte, J.; et al. CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein. Br. J. Cancer 1998, 77 (3), 359-365.
44. Chen, A.Y.; Yu, C.; Potmesil, M.; et al. Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res. 1991, 51 (22), 6039-6044.
45. Kondratov, R.; Komarov, P.O.; Becker, Y.; et al. Small molecules that dramatically alter multidrug resistance phenotype by modulating the substrate specificity of P-glycoprotein. Proc. Natl. Acad. Sci. U. S. A. 2001, 98, 14078-14083.
46. Mahon, F.X.; Deininger, M.W.; Schultheis, B.; et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000, 96 (3), 1070-1079.
47. Politi, P.M.; Arnold, ST.; Felsted, R.L.; et al. P-glycoprotein- independent mechanism of resistance to VP-16 in multidrug-resistant tumor cell lines: pharmacokinetic and photoaffinity labeling studies. Mol. Pharmacol. 1990, 37 (6), 790-796.
48. Krishna, R.; Mayer, L.D. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci. 2000, 11 (4), 265-283.
49. Newman, M.J.; Rodarte, J.C.; Benbatoul, K.D.; et al. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Res. 2000, 60 (11), 2964-2972.
50. Olson, D.P.; Scadden, D.T.; D'Aquila, R.T.; et al. The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1). AIDS 2002, 16 (13), 1743-1747.
51. Bergmann, R.; Brust, P.; Johannsen, B. Differentiation between specific and nonspecific effects related to P-glycoprotein inhibition in immortalized rat brain endothelial cells. Int. J. Clin. Pharmacol. Ther. 1998, 36, 46-49.
52. Trump, D.L.; Smith, D.C.; Ellis, P.G.; et al. High-dose oral tamoxifen, a potential multi-drug reversal agent: phase I trial in combination with vinblastine. J. Natl. Cancer Inst. 1992, 84, 1811-1816.
53. Wang, E.J.; Casciano, C.N.; Clement, R.P.; et al. In vitro flow cytometry method to quantitatively assess inhibitors of P-glycoprotein. Drug Metab. Dispos. 2000, 28, 522-528.
54. Maliepaard, M.; van Gastelen, M.A.; Tohgo, A.; et al. Circumvention of BCRP-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin. Cancer Res. 2001, 7, 935-941.
55. Smeets, M.E.; Raymakers, R.A.; Vierwinden, G.; et al. Idarubicin DNA intercalation is reduced by MRP1 and not Pgp. Leukemia 1999, 9, 1390-1398.
56. Utz, L; Spitaler, M.; Rybczynska, M.; et al. Reversal of multidrug resistance by the staurosporine derivatives CGP 41251 and CGP 42700. Int. J. Cancer 1998, 77 (1), 64-69.
57. Jedlitschky, G.; Keppler, G. Transport of leukotriene C4 and structurally related conjugates. Vitam. Horm. 2002, 64, 153-184.
58. Dantzig, A.H.; Law, K.L.; Cao, J.; et al. Reversal of multidrug resistance by the P-glycoprotein modulator, LY335979, from the benc to the clinic. Curr. Med. Chem. 2001, 1, 39-50.
59. Ishikawa, T.; Ali-Osman, F. Glutathione-associated cis- diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. J. Biol. Chem. 1993, 268 (27), 20116-20125.
60. Zeng, H.; Chen, Z.S.; Belinsky, M.G.; et al. Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001, 61 (19), 7225-7232.
61. Cole, S.P.; Sparks, K.E.; Fraser, K.; et al. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res. 1994, 15 (54 (22)), 5902-5910.
62. Marbeuf-Gueye, C.; Broxterman, H.J.; Dubru, F.; et al. Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells. Mol. Pharmacol. 1998, 53 (1), 141-147.
63. Maliepaard, M.; van Gastelen, M.A.; de Jong, L.A.; et al. Over-expression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res. 1999, 59, 4559-4563.
64. Rappa, G.; Lorico, A.; Flavell, R.A.; et al. Evidence that the multidrug resistance protein (MRP) functions as a co-transporter of glutathione and natural product toxins. Cancer Res. 1997, 57 (23), 5232-5237.
65. König, J.; Nies, A.T.; Cui, Y.; et al. Conjugate export pump of the MRP family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim. Biophys. Acta 1999, 1416, 377-394.
66. Diah, S.K.; Smitherman, P.K.; Aldridge, J.; et al. Resistance to mitoxantrone in multidrug-resistant MCF7 breast cancer cells: evaluation of mitoxantrone transport and the role of multidrug resistance protein family proteins. Cancer Res. 2001, 61 (14), 5461-5467.
67. Ishikawa, T. The ATP-dependent glutathione S-conjugate export pump. Trends Biochem. Sci. 1992, 17, 463-468.
68. Müller, M.; Meijer, C.; Zaman, G.J.R.; et al. Overexpression of the gene encoding the multidrug resistance-associated protein results in increases ATP-dependent glutathione S-conjugate transport. Proc. Natl. Acad. Sci. U. S. A. 1994, 91, 13033-13037.
69. Atkinson, C.D.E.; Sibley, C.P.; Greenwood, S.L. Comparison of multidrug resistance activity in two choriocarcinoma-derived cell lines. J. Physiol. 2001, 535P, S019.
70. Leier, L; Jedlischky, G.; Buchholz, U.; et al. The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J. Biol. Chem. 1994, 269, 27807-27810.
71. Dallas, S.; Zhu, X.; Baruchel, S.; et al. Functional expression of the multidrug resistance protein 1 (MRP1) in microglia. J. Pharmacol. Exp. Ther. 2003, 307 (1), 282-290.
72. Chen, X.J.; Bauer, B.E.; Kuchler, K.; et al. Positive and negative control of multidrug resistance by the Sit4 protein phosphatase in kluyveromyces lactis. J. Biol. Chem. 2000, 275 (20), 14865-14872.
73. Norman, B.H.; Gruber, J.M.; Hollinshead, S.P.; et al. Tricyclic isoxazoles ar novel inhibitors of the multidrug resistance protein (MRP1). Bioorg. Med. Chem. Lett. 2002, 12, 883-886.
74. Evers, R.; Cnubben, N.H.; Wijnholds, J.; et al. Transport of glutathione prostaglandin A conjugates by the multidrug resistance protein 1. FEES Lett. 1997, 419 (1), 112-126.
75. Hamilton, K.O.; Topp, E.; Makagiansar, I.; et al. Multidrug resistance-associated protein-1 functional activity in Calu-3 cells. J. Pharmacol. Exp. Ther. 2001, 29S (3), 1199-1205.
76. Lehmann, T.; Kohler, C.; Weidauer, E.; et al. Expression of MRP1 and related transporters in human lung cells in culture. Toxicology 2001, 167 (1), 59-72.
77. Assaraf, Y.G.; Rothem, L.; Hooijberg, J.H.; et al. Loss of multidrug resistance protein 1 expression and folate efflux activity results in a highly concentrative folate transport in human leukemia cells. J. Biol. Chem. 2003, 278 (9), 6680-6686.
78. Peck, R.A.; Hewett, J.; Harding, M.W.; et al. Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin. J. Clin. Oncol. 2001, 19 (12), 3130-3141.
79. Burg, D.; Wielinga, P.; Zelcer, N.; et al. Inhibition of the multidrug resistance protein 1 (MRP1) by peptidomimetic glutathione-conjugate analogs. Mol. Pharmacol. 2002, 62 (5), 1160-1166.
80. Borst, P.; Evers, R.; Kool, M.; et al. A family of drug transporters: the multidrug reistance-associated proteins. J. Natl. Cancer Inst. 2000, 92, 1295-1302.
81. Korke, K.; Kawabe, T.; Tanaka, T.; et al. A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res. 1997, 57 (24), 5475-5479.
82. Cui, Y.; Konig, J.; Bucholz, J.K.; et al. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol. Pharmacol. 1999, 55 (5), 929-937.
83. Kool, M.; van der Linden, M.; de Haas, M.; et al. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 6914-6919.
84. Hooijberg, J.H.; Broxterman, H.J.; Kool, M.; et al. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 1999, 59 (11), 2532-2535.
85. Homolya, L.; Varadi, A.; Sarkadi, B. Multidrug resistance-associated proteins: export pumps for conjugates with glutathione, glucuronate or sulfate. Biofactors 2003, 17 (1-4), 103-114.
86. Evers, R.; Kool, M.; van Deemter, L.; et al. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J. Clin. Invest. 1998, 101 (7), 1310-1319.
87. Horikawa, M.; Kato, Y.; Tyson, C.A.; et al. The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenicid as a candidate inhibitor of the biliary excretion of irinotecan metabolites. Drug Metab. Pharmacokineti. 2002, 17 (1), 23-33.
88. Chen, Z.-S.; Akiyama, S.I.; Aoki, S.; et al. Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. Mol. Pharmacol. 1999, 56 (6), 1219-1228.
89. Horikawa, M.; Kato, Y.; Tyson, C.A.; et al. Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenicid in rats. Pharm. Res. 2002, 9, 1345-1353.
90. Evers, R.; de Haas, M.; Sparidans, R.; et al. Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br. J. Cancer 2000, 83 (3), 375-383.
91. Hirohashi, T.; Suzuki, H.; Sugiyama, Y. Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3). J. Biol. Chem. 1999, 274 (21), 15181-15185.
92. Zeng, H.; Bain, L.J.; Belinsky, M.G.; et al. Expression of multidrug resistance protein-3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer agents. Cancer Res. 1999, 59, 5964-5967.
93. Zeng, H.; Liu, G.; Rea, P.A.; et al. Transport of amphipathic anions by human multidrug resistance protein 3. Cancer Res. 2000, 60, 4770-4784.
94. Zelcer, N.; Saeki, T.; Reid, G.; et al. Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J. Biol. Chem. 2001, 276, 46400-46407.
95. Yang, B.; Hill, C.E. Nifedipine modulation of biliary GSH and GSSG/conjugate efflux in normal and regenerating rat liver. Am. J. Physiol.: Gastrointest. Liver 2001, 281, G85-G94.
96. Allen, J.D.; Jackson, S.C.; Schinkel, A.H. A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for doxorubicin resistance. Cancer Res. 2002, 62 (8), 2294-2299.
97. Litman, T.; Brangi, M.; Hudson, E.; et al. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J. Cell. Sci. 2000, 113, 2011-2021.
98. Brangi, M.; Litman, T.; Ciotti, M.; et al. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation MXR-expressing cells. Cancer Res. 1999, 59, 5938-5946.
99. Pratesi, G.; Laccabue, D.; Lanzi, C. IDN 5390: an oral taxane candidate for protracted treatment schedules. Br. J. Cancer 2003, 88, 965-972.
100. Rabindran, S.K.; Ross, D.D.; Doyle, L.A.; et al. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res. 2000, 60, 47-50.
101. Allen, J.D.; Loevezijn, A.; Lakhai, J.M.; et al. Potent and specific inhibition of the breast cancer resistance multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Cancer Ther. 2002, 6, 417-425.
102. Bhat, U.G.; Winter, M.A.; Pearce, H.L.; et al. A structure-function relationship among reserpine and yohimbine analogues in their ability to increase expression of mdrl and P-glycoprotein in a human colon carcinoma cell line. Mol. Pharmacol. 1995, 48 (4), 682-689.
103. Leonard, G.D.; Polgar, O.; Bates, S. ABC transporters and inhibitors: new targets, new agents. Curr. Opin. Investig. Drugs 2002, 3 (11), 1652-1659.
104. Borst, P.; Evers, R.; Kool, M.; et al. The multidrug resistance protein family. Biochim. Biophys. Acta 1999, 1461, 347-357.
105. Gottesman, M.M.; Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 1993, 62, 385-427.
106. Dantzig, A.H.; de Alwis, D.H.; Burgess, M. Considerations in the design and development of transport inhibitors as adjuncts to drug therapy. Adv. Drug Deliv. Rev. 2003, 55, 133-140.
107. Thomas, H.; Coley, H.M. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 2003, 2, 159-165.
108. http://bigfoot.med.unc.edu/watkinsLab/website/intesinfo.htm (accessed January 2004).
109. Fisher, G.A.; Lum, B.L.; Hausdorff, J.; et al. Pharmacological considerations in the modulation of multidrug resistance. Eur. J. Cancer 1996, 32A (6), 1082-1088.
110. Lum, B.; Gosland, M. MDR expression in normal tissues. Pharmacological implications for the use of P-glycoprotein inhibitors. Hematol./ Oncol. Clin. North Am. 1995, 9 (2), 319-336.
111. Fojo, A.T.; Ueda, K.; Slamon, D.J.; et al. Expression of a multidrug-resistance gene in human tumors and tissues. Proc. Natl. Acad. Sci. U. S. A. 1997, 84 (1), 265-269.
112. Lown, K.S.; May, R.R.; Leichtman; et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin. Pharmacol. Ther. 1997, 62, 248-260.
113. Lown, K.S.; Kolars, J.C.; Thummel, K.E.; et al. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab. Dispos. 1994, 22, 947-955.
114. Masuda, S.; Uemoto, S.; Hahida, T.; et al. Effects of intestinal P-glycoprotein on daily tacrolimus through level in a living-donor small bowel recipient. Clin. Pharmacol. Ther. 2000, 68, 98-103.
115. Chan, H.S.L.; Haddad, G.; Thorner, P.S.; et al. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N. Engl. J. Med. 1991, 325, 1608-1614.
116. Baekelandt, M.M.; Holm, R.; Nesland, J.M.; et al. P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer. Anticancer Res. 2000, 20 (2B), 1061-1067.
117. Abolhoda, A.; Wilson, A.E.; Ross, H.; et al. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin. Cancer Res. 1999, 5 (11), 3352-3356.
118. Baldini, N.; Scotlandi, K.; Barabanti-Brodano, G.; et al. Expression of P-glycopfotein in high-grade osteosarcomas in relation to clinical outcome. N. Engl. J. Med. 1995, 333, 1380-1385.
119. Hoffmeyer, S.; Burk, O.; von Richter, O.; et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 3473-3478.
120. Shapiro, A.B.; Ling, V. Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur. J. Biochem. 1997, 250, 130-137.
121. Yudoh, K.; Matsuno, H.; Nakazawa, F.; et al. Increased expression of multidrug resistance of P-glycoprotein on Th1 cells correlates with drug resistance in rheumatoid arthritis. Arthritis Rheum. 1999, 42 (9), 2014-2015.
122. Gifford, A.J.; Kavallaris, M.; Madafiglio, J.; et al. P-glycoprotein-mediated methotrexate resistance in CCRF-CEM sublines deficient in methotrexate accumulation due to point mutation in the reduced folate carrier gene. Int. J. Cancer 1998, 78 (2), 176-181.
123. Cummins, C.L.; Jacobsen, W.; Benet, L.Z. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J. Pharmacol. Exp. Ther. 2002, 300, 1036-1045.
124. Sekine, I.; Saijo, N. Polymorphisms of metabolizing and transporter proteins involved in the clearance of anticancer agents. Ann. Oncol. 2001, 12, 1515-1525.
125. www.kuhp.kyoto-u.ac.jp/~yakuzai/english.html, (accessed January 2004).
126. Saito, H.; Masuda, S.; Inui, K. Cloning and functional characterization of a novel rat organic anion transporter mediating basolateral uptake of methotrexate in the kidney. J. Biol. Chem. 1996, 271, 20719-20725.
127. Basu, E.; Takeda, M.; Narikawa, S.; et al. Characterization of ochratoxin A transport by human organic anion transporter. Biochim. Biophys. Acta, in press.
128. Cha, S.H.; Sekine, T.; Fukushima, J.I.; et al. Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol. Pharmacol. 2001, 59, 1277-1286.
129. Kobayashi, Y.; Ohshiro, N.; Shibusawa, A.; et al. Isolation, characterization and differential gene expression of multispecific organic anion transporter 2 in mice. Mol. Pharmacol. 2002, 62 (1), 7-14.
130. Sweet, D.H.; Chan, L.M.; Walden, R.; et al. Organic anion transporter 3 (Slc22a8) is a dicarboxylate exchanger indirectly coupled to the Na+ gradient. Am. J. Physiol., Renal Physiol. 2003, 284 (4), F763-F769.
131. Tamia, I.; Nezu, J.; Uchino, H.; et al. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem. Biophys. Res. Commun. 2000, 273, 251-260.
132. Abe, T.; Kakyo, M.; Tokui, T.; et al. Identification of a new gene family encoding human liver-specific organic anion transporter LST-1. J. Biol. Chem. 1999, 274, 17159-17163,
133. Ugele, B.; St-Pierre, M.V.; Pihusch, M.; et al. Characterization and identification of steroid sulfate transporters of human placenta. Am. J. Physiol.: Endocrinol. Metab. 2003, 284 (2), E390-E398.
134. Perri, D.; Ito, S.; Rowsell, V.; et al. The kidney. The body's playground for drugs: an overview of renal drug handling with selected clinical correlates. Can. J. Clin. Pharmacol. 2003, 10 (1), 17-23.
135. Fei, Y.J.; Kanai, Y.; Nussberger, S.; et al. Expression cloning of a mammalian proton-coupled oligopeptide transporter. Nature 1994, 368, 563-566.
136. Saito, H.; Okuda, M.; Terada, T.; et al. Cloning and characterization of rat H+/peptide cotransporter mediating absorption of B-lactam antibiotics in the intestine and kidney. J. Pharmacol. Exp. Ther. 1995, 275, 1631-1637.
137. Sai, Y.; Tamai, I.; Sumikawa, H.; et al. Immunolocalization and pharmacological relevance of oligopeptide transporter PepT1 in intestinal absorption of B-lactam antibiotics. FEBS Lett. 1996, 392, 25-29.
138. Liu, W.; Lian, R.; Ramamoorthy, S.; et al. Molecular cloning of PEPT2, a new member of the H+/peptide cotransporter family, from human kidney. Biochim. Biophys. Acta 1995, 1235, 461-466.
139. Obata, T.; Endo, Y.; Murata, D.; et al. The molecular targets of antitumor 2′-deoxycytidine analogues. Drug Targets 2003, 4 (4), 305-313.
140. Chen, R.; Nelson, J.A. Role of organic cation transporters in the renal secretion of nucleotides. Biochem. Pharmacol. 2000, 60, 215-219.
141. Jonker, J.W.; Wagenaar, E.; Mol, C.A.A.M.; et al. Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct 1 [Slc22a1]) gene. Mol. Cell. Biol. 2001, 21 (16), 5471-5477.
142. Okuda, M.; Saito, H.; Urakami, Y.; et al. cDNA cloning and functional expression of a novel rat kidney organic cation transporter, OCT2. Biochem. Biophys. Res. Commun. 1996, 224, 500-507.
143. Zhang, L.; Dresser, M.J.; Gray, A.T.; et al. Cloning and functional expression of a human liver organic cation transporter. Mol. Pharmacol. 1997, 57, 913-921.
144. Verhaagh, S.; Schweifer, N.; Barlow, D.P.; et al. Cloning of the mouse and human solute carrier 22a3 (Slc22a/SLC22A3) identifies a conserved cluster of three organic cation transporters on mouse chormosome 17 and human 6q26-q27. Genomics 1999, 55, 209-218.
145. Kekuda, R.; Prasad, P.D.; Wu, X.; et al. Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta. J. Biol. Chem. 1998, 273, 15971-15979.
146. Mackay, J.R.; Jennings, L.L.; Clarke, M.L.; et al. Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers. Clin. Cancer Res. 2002, 8, 110-116.
147. Mata, J.F.; Garcia-Manteiga, J.M.; Lostao, M.P.; et al. Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5′-deoxy-5-fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug. Mol. Pharmacol. 2001, 6, 1542-1548.
148. Ruegg, C.; Zaric, J.; Stupp, R. Non steroidal anti-inflammatory drugs and COX-2 inhibitor anti-cancer therapeutics: hypes, hopes and reality. Ann. Med. 2003, 35 (7), 476-487.
149. Xu, X.C. COX-2 inhibitors in cancer treatment and prevention, a recent development. Anti-cancer Drugs 2002, 2, 127-137.
150. Tsuji, A. Transporter-mediated drug interactions. Drug Metab. Pharmacokineti. 2002, 17 (4), 253-274.
151. List, A.F.; Kopecky, K.J.; Willman, C.L.; et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 2001, 98 (12), 3212-3220.
152. Loe, D.W.; Deeley, R.G.; Cole, S.P.C. Characterization of vincristine transport by the Mr 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. Cancer Res. 1998, 5S, 5130-5136.
153. Millward, M.J.; Cantwell, B.M.; Munro, N.C.; et al. Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study. Br. J. Cancer 1993, 67 (5), 1031-1035.
154. Gutmann, H.; Flicker, G.; Drewe, J.; et al. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol. Pharmacol. 1999, 56, 383-389.
155. Hanko, E.; Tommarello, S.; Watchko, J.F.; et al. Administration of drug known to inhibit P-glycoprotein increases brain bilirubin and alters the regional distribution of bilirubin in rat brains. Pediatr. Res. 2003, 54 (4), 441-445.
156. Hofsli, E.; Nissen-Meyer, J. Reversal of drug resistance by erythromycin: erythromycin increases the accumulation of actinomycin D and doxorubicin in multidrug-resistant cells. Int. J. Cancer 1989, 44 (1), 149-154.
157. Barnes, K.M.; Dickstein, B.; Cutler, G.B., Jr.; et al. Steroid treatment, accumulation, and antagonism of P-glycoprotein in multidrug-resistant cells. Biochemistry 1996, 35 (15), 4820-4827.
158. Kakumoto, M.; Takara, K.; Sakaeda, T.; et al. MDR1-mediated interaction of digoxin with antiarrhythmic or antianginal drugs. Biol. Pharm. Bull. 2002, 12, 1604-1607.
159. Rege, B.D.; Kao, J.P.; Polli, J.E. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur. J. Pharm. Sci. 2002, 4-5, 237-246.
160. Kim, R.B.; Wandel, C.; Leake, B.; et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm. Res. 1999, 3, 408-414.
161. Wigler, P.W.; Lyon, K.L.; Patterson, F.K.; et al. Epoxide metabolite of quinine and inhibition of the multidrug resistance pump in human leukemic lymphoblasts. Mol. Pharmacol. 1994, 46 (3), 562-567.
162. www.humanabc.org, (accessed January 2004).
163. Borst, P.; Oude Elferink, R.P.J. Mammalian ABC transporters in health and disease. Annu. Rev. Biochem. 2002, 71, 537-595.
164. Guo, A.; Marinaro, W.; Hu, P.; et al. Delineating the contribution of secretory transporters in the efflux of etoposide using madin-darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1) and canalicular multi-specific organic anion transporter (cMoat). Drug Metab. Dispos. 2002, 30, 457-463.
165. Paul, S.; Breuninger, L.M.; Tew, K.D.; et al. ATP-dependent uptake of natural product cytotoxic drugs by membrane vesicles establishes MRP as a broad specificity transporter. Proc. Natl. Acad. Sci. U. S. A. 1996, 93, 6929-6934.
166. Allen, J.D.; Brinkhuis, R.F.; Deemter, L.; et al. Extensive contribution of the multidrug transporters P-glycoprotein and MRP1 to basal drug resistance. Cancer Res. 2000, 60, 5761-5766.
167. Wijnholds, J.; Scheffer, G.L.; van der Valk, P.; et al. Multidrug resistance protein 1 protects the oropharyngeal mucosal layer and the testicular tubules against drug-induced damage. J. Exp. Med. 1998, 188, 797-808.
168. Bordow, S.B.; Haber, M.; Madafiglio, J.; et al. Expression of the multidrug resistance-associated protein (MRP) gen correlates with amplification and overexpression of the N-mye oncogene in childhood neuroblastoma. Cancer Res. 1994, 53, 5036-5040.
169. Nooter, K.; Westerman, A.M.; Flens, M.J.; et al. Expression of the
170. Ota, E.; Abe, Y.; Oshika, Y.; et al. Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer. Br. J. Cancer 1995, 72 (3), 550-554.
171. Endo, K.; Maehara, Y.; Kusumoto, T.; et al. Expression of multidrug resistance-associated protein (MRP) and chemosensitivity in human gastric cancer. Int. J. Cancer 1996, 68, 372-377.
172. Filipits, M.; Suchomel, R.W.; Kekan, G.; et al. MRP and MDR1 gene expression in primary breast carcinomas. Clin. Cancer Res. 1996, 2, 1231-1237.
173. Morris, M.D.; Bordow, S.B.; Marshall, G.M.; et al. Expression of the gene of multidrug-resistance-associated protein and outcome in patiens with neuroblastoma. N. Engl. J. Med. 1996, 334, 231-238.
174. Nakagawa, M.; Emoto, A.; Hanada, T.; et al. Clinical significance of multidrug resistant protein (MRP) and P-glycoprotein patients with bladder cancers. J. Urol. 1997, 157, 1260-1264.
175. Ito, K.; Fujimori, M.; Nakata, S.; et al. Clinical significance of the increased multidrug resistance-associated protein (MRP) gene expression in patients with primary breast cancer. Oncol. Res. 1998, 10, 99-109.
176. Legrand, O.; Simonin, G.; Beauchamp-Nicoud, A.; et al. Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult aute myeloid leukemia. Blood 1999, 94 (3), 1046-1056.
177. van der Kolk, D.M.; de Vries, E.G.; van Putten, W.J.; et al. P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia. Clin. Cancer Res. 2000, 6 (8), 3205-3215.
178. Conrad, S.; Kaufman, H.-M.; Ito, K.; et al. Identification of human multidrug resistance protein 1 (MRP1) mutations and characterization of a G671V substitution. J. Hum. Genet. 2001, 46, 656-663.
179. Zaman, G.J.R.; Lankelma, J.; van Tellingen, O.; et al. Role of glutathione in the export of compounds form cells by the multidrug-resistance- associated-protein. Proc. Natl. Acad. Sci. U. S. A. 1995, 92, 7690-7694.
180. Sakamoto, H.; Hara, H.; Hirano, K.; et al. Enhancement of glucuronyl etoposide transport by glutathione in multidrug resistance-associated protein-overexpressing cells. Cancer Lett. 1999, 135 (1), 113-119.
181. Leslie, E.M.; Deeley, R.G.; Cole, S.P. Bioflavonoid stimulation of glutathione transport by the 190 kDa multidrug resistance protein 1 (MRP1). Drug Metab. Dispos. 2003, 1, 11-15.
182. Keppler, D.; Leier, I.; Jedlitschky, G. Transport of glutathione conjugates and glucuronides by the multidrug resistance proteins MRP1 and MRP2. Biol. Chem. 1997, 378, 787-791.
183. Evers, R.; Kool, M.; van Deemter, L.; et al. Drug export of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J. Clin. Invest. 1998, 101, 1310-1319.
184. St-Pierre, M.V.; Serrano, M.A.; Macias, R.I.; et al. Expression of members of the multidrug resistance protein family in human term placenta. Am. J. Physiol. 2000, 279, R1495-R1503.
185. Arts, H.J.; Katsaros, D.; de Vries, E.G.; et al. Drag resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associate protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma. Clin. Cancer Res. 1999, 5, 2798-2805.
186. Hinoshita, E.; Uchiumi, T.; Taguchi, K.; et al. Increase expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas. Clin. Cancer Res. 2000, 6, 2401-2407.
187. van der Kolk, D.M.; Vellenga, E.; van der Veen, A.Y.; et al. Deletion of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myloid leukaemia. Blood 2000, 95, 3514-3519.
188. van der Kolk, D.M.; de Vries, E.G.; Noordhoek, L.; et al. Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myloid leukemia. Leukemia 2001, 15, 1544-1553.
189. Soini, Y.; Jarvinen, K.; Kaareenaho-Wiik, R.; et al. The expression of P-glycoprotein and multidrug resistance proteins and 2 (MRP1 and MRP2) in human malignant mesothelioma. Ann. Oncol. 2001, 12, 1239-1245.
190. Nies, A.T.; Konig, J.; Pfannschmidt, M.; et al. Expression of the multidrug resistance proteins MRP2 and MPR3 in human hepatocellular carcinoma. Int. J. Cancer 2001, 94, 492-499.
191. Kool, M.; de Haas, M.; Scheffer, L.; et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologs of the multidrug resistance-associated resistance protein (MRP1), in human cancer cell lines. Cancer Res. 1997, 57, 3537-3547.
192. Paulusma, C.C.; Bosma, P.J.; Zaman, G.J.R.; et al. Congenital jaundice in rats with amutation in a multidrug resistance-associated protein gene. Science 1996, 271, 1126-1128.
193. Keppler, D.; Kartenbeck, J. The canalicular conjugate export pump encoded by the cmrp/cmoat gene. Prog. Liver Dis. 1996, 14, 55-67.
194. From, M.F.; Kauffman, H.-M.; Fritz, P.; et al. The effect of rifampin treatment of intestinal expression of human MRP transporters. Am. J. Pathol. 2000, 157 (5), 1575-1579.
195. Kaufmann, H.M.; Keppler, D.; Kartenbeck, J.; et al. Induction of cMrp/ cMoat gene expression by cisplatin, 2-acetylaminofluorene, or cycloheximide in rat hepatocytes. Hepatology 1997, 25, 1123-1129.
196. Strayhorn, V.A.; Baciewicz, A.M.; Self, T.H. Update on rifampin drug interactions. III. Arch. Intern. Med. 1997, 157, 2453-2458.
197. Chu, X.Y.; Kato, Y.; Sugiyama, Y. Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11 and its metabolites in rats. Cancer Res. 1997, 57, 1934-1938.
198. Zelcer, N.; Huisman, M.T.; Reid, G.; et al. Evidence for two interacting ligand-binding sites in human MRP2 (ATP binding cassette C2). J. Biol. Chem. 2003, 278 (26), 23538-23544.
199. Decleves, X.; Fajac, A.; Lehmann-Che, J.; et al. Molecular and functional MDR1-Pgp and MPRs expression in human glioblastoma multiforme cell lines. Int. J. Cancer 2002, 98 (2), 173-180.
200. Bodo, A.; Bakos, E.; Szeri, F.; et al. The role of multidrug transporters in drug availability, metabolism and toxicity. Toxicol. Lett. 2003, 140-141, 133-143.
201. Suzuki, H.; Sugiyama, Y. Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCG2): its impact on drug disposition. Adv. Drug Deliv. Rev. 2002, 54, 1311-1331.
202. Sasaki, M.; Suzuki, H.; Ito, K.; et al. Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and multidrug resistance-associated protein2 (MRP2/ABCC2). J. Biol. Chem. 2002, 17 (1), 23-33.
203. König, J.; Rost, D.; Cur, Y.; et al. Characterization of the human multidrug resistance-associated protein 3 (MRP3). J. Biol. Chem. 1999, 29, 1156-1163.
204. Scheffer, G.L.; Kool, M.; de Haas, M.; et al. Tissue distribution and induction of human MRP3. Lab. Invest. 2002, 82, 193-201.
205. Rost, D.; König, J.; Weiss, G.; et al. Expression and localization of the multidrug resistance proteins mrp2 and mrp3 in human gallbladder epithelia. Gastroenterology 2001, 121, 1203-1208.
206. Ohishi, Y.; Oda, Y.; Uchiumi, T.; et al. ATP-binding cassette superfamily transporter gene expression in human primary ovarina carcinoma. Clin. Cancer Res. 2002, 12, 3767-3775.
207. Steinbach, D.; Lengemann, J.; Voight, A.; et al. Response to chemotherapy and expression of the genes encoding the multidrug resistance-associated proteins MRP2, MRP3, MRP4, MRP5 and SMRP in childhood acute myeloid leukemia. Clin. Cancer Res. 2003, 3, 1083-1086.
208. Hiroshashi, T.; Suzuki, H.; Ito, K.; et al. Hepatic expression of multidrug resistance-associated protein-like proteins maintained in eisai hyperbilirubinemic rats. Mol. Pharmacol. 1998, 53, 1068-1075.
209. Lee, K.; Belinsky, M.G.; Bell, D.W.; et al. Isolation of MOAT-B, a widely expressed multidrug resistance-associated protein/canalicular multispecific organic anion transporter-related transporter. Cancer Res. 1998, 58, 2741-2747.
210. Aubel van, R.A.M.H.; Smeets, P.H.E.; Peters, J.G.P.; et al. The MRP4/ ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubule: the putative efflux pump for urinary cAMP and cGMP. Soc. Nephrol. 2002, 13, 595-603.
211. Lee, K.; Klein-Szanto, A.J.P.; Kruh, G.D. Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells. J. Natl. Cancer Inst. 2000, 92, 1934-1940.
212. Chen, Z.-S.; Lee, G.D.; Kruh, G.D. Transport of cyclic nucleotide and estradiol 17-B-D glucuronide by multidrug resistance protein 4. J. Biol. Chem. 2001, 276, 33747-33754.
213. Chen, Z.-S.; Lee, K.; Walther, S.; et al. Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4). Cancer Res. 2002, 62 (11), 3144-3150.
214. Wijnholds, J.; Mol, C.A.A.M.; van Deemter, L.; et al. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc. Natl. Acad. Sci. U. S. A. 2000, 97 (13), 7476-7481.
215. McAleer, M.A.; Breen, M.A.; White, N.L.; et al. pABC11 (also known as MOAAT-C and MRP5) a member of the ABC family of proteins, has anion transporter activity but does not conver multidrug resistance when overexpressed in human embyronic kidney 293 cells. J. Biol. Chem. 1999, 274, 23541-23548.
216. Belinsky, M.G.; Bain, L.J.; Balsara, B.B.; et al. Characterization of MOAT-C and MOAT-D, new members of the MRP/cMOAT subfamily of transporter proteins. J. Natl. Cancer Inst. 1998, 90, 1735-1741.
217. Suzuki, T.; Nishio, K.; Sasaki, H.; et al. cDNA cloning of a short type of multidrug resistance protein homologue, SMRP, from a human lung cancer cell line. Biochem. Biophys. Res. Commun. 1997, 238, 790-794.
218. Sampath, J.; Adachi, M.; Hatse, S.; et al. Role of MRP4 and MRP5 in biology and chemotherapy. AAPS PharmSci 2002, 4 (3), 1-8, article 14.
219. Yoshida, M.; Suzuki, T.; Komiya, T.; et al. Induction of MRP5 and SMRP mRNA by adriamycin exposure and its overexpression in human lung cancer cells resistant to adriamycin. Int. J. Cancer 2001, 94 (3), 432-437.
220. Oguri, T.; Isobe Suzuki, T.; Nishio, K.; et al. Increased expression of the MRP5 gene is associated with exposure to platinum drugs in lung cancer. Int. J. Cancer 2000, 86, 95-100.
221. Wielinga, P.R.; van der Heijden, I.; Reid, G.; et al. Characterization of the MRP4- and MRP5-mediated transport of cyclic nucleotide from intact cells. J. Biol. Chem. 2003, 278 (20), 17664-17671.
222. Wijnholds, J.; de Lange, E.C.; Scheffer, G.L.; et al. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Clin. Investig. 2000, 105, 279-285.
223. Ejendal, K.F.K.; Krycyna, C.A. Multidrug resistance and cancer: the role of the human ABC transporter ABCG2. Curr. Protein Pept. Sci. 2002, 3, 503-511.
224. Taipalensuu, J.; Tornblom, H.; Lindberg, G.; et al. Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J. Pharmacol. Exp. Ther. 2001, 299, 164-170.
225. Jonker, J.W.; Buitelaar, M.; Wagenaar, E.; et al. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc. Natl. Acad. Sci. U. S. A. 2002, 99, 15649-15654.
226. Hendricks, C.B.; Rowinsky, E.K.; Growchow, L.B.; et al. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res. 1992, 52, 2268-2278.
227. Scharenberg, C.W.; Hareky, M.A.; Torok-Storb, B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature hematopoieteic progenitors. Blood 2002, 99, 507-512.
228. Bunting, K.D. ABC transporters as phenotyic markers and functional regulators of stem cells. Stem Cells 2002, 20, 11-20.
229. Zhou, S.; Shuetz, J.D.; Bunting, K.D.; et al. The ABC transporter Bcrpl/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat. Med. 2001, 7 (9), 1028-1034.
230. Litman, T.; Brangi, M.; Hudson, E.; et al. The multidrug-resistance phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J. Cell. Sci. 2000, 113, 2011-2021.
231. Allen, J.D.; Brinkhuis, R.F.; Wijnholds, J.; et al. The mouse Bcrp/Mxr/ Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res. 1999, 59, 4237-4241.
232. Ross, D.D.; Yang, W.; Abruzzo, L.V.; et al. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J. Natl. Cancer Inst. 1999, 91, 429-433.
233. Kawabata, S.; Oka, M.; Shiozawa, K.; et al. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem. Biophys. Res. Commun. 2001, 280, 1216-1223.
234. Robey, R.W.; Medina-Perez, W.Y.; Nishiyama, K.; et al. Over-expression of the ATP-binding cassette half-transporter, ABCG2 (MXR/BCRP/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin. Cancer Res. 2001, 7, 145-152.
235. Doyle, L.A.; Yang, W.; Abruzzo, L.V.; et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 1998, 95, 15665-15670.
236. Hazlehurst, L.A.; Foley, N.E.; Gleason-Guzman, M.C.; et al. Multiple mechanisms confer drug resistance to the human 8226 myeloma cell line. Cancer Res. 1999, 59, 1021-1028.
237. Rabindran, S.K.; He, H.; Singh, M.; et al. Reversal of a novel multidrug resistance mechanisms in human colon carcinoma cells b fumitremorgin C. Cancer Res. 1998, 58, 5850-5858.
238. Sargent, J.M.; Williamson, C.J.; Maliepaard, M.; et al. Breast cancer resistance protein expression and resistance to daunorubicin in blast cells from patients with acute myeloid leukaemia. Br. J. Haematol. 2001, 115, 257-262.
239. Ozvegy, C.; Litman, T.; Szakacs, G.; et al. Functional characterization of the human multidrug transporter, ABCG2 expressed in insect cells. Biochem. Biophys. Res. Commun. 2001, 285, 111-117.
240. Kruijtzer, C.M.F.; Beijnen, J.H.; Schellens, J.H.M. Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 (CYP) in the gastrointestinal tract and liver. An overview. Oncologist 2002, 7 (6), 516-530.
241. Kruijtzer, C.M.F.; Beijnen, J.H.; Rosing, H.; et al. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J. Clin. Oncol. 2002, 20, 2943-2950.
242. Inui, K.; Masuda, S.; Saito, H. Cellular and molecular aspects of drug transport in the kidney. Kidney Int. 2000, 58, 944-958.
243. Chen, X.; Li, N.; Wang, S.; et al. Leukotrien A4 hydrolase in rat and human esophageal adenocarcinomas and inhibitory effects of bestatin. J. Natl. Cancer Inst. 2003, 95 (14), 1053-1061.
244. Ichinose, Y.; Genka, K.; Koike, T.; NK421 Lung Cancer Surgery Group. Randomized double-blind placebo-controlled trial of bestatin in patients with resected stage 1 squamous-cell lung carcinoma. J. Natl. Cancer Inst. 2003, 95 (8), 605-610.
245. Nakanishi, T.; Tamai, I.; Sai, Y.; et al. A carrier-mediated transport of oligopeptides in the human fibrosarcoma cell line HT1080. Cancer Res. 1997, 58, 4118-4122.
246. Nakanishi, T.; Tamai, I.; Takagi, A.; et al. Cancer cell-targeted drug delivery utilizing oligopeptide transport activity. Int. J. Cancer 2000, 88, 274-280.
247. Wrighton, S.A.; Van den Branden, M.; Ring, B.J. The human drug metabolizing cytochromes P450. J. Pharmacokinet. Biopharm. 1996, 24, 461-473.
248. Zhang, Y.; Benet, L.Z. The gut as a barrier to drug absorption. Combined role of cytochrome P450 3A and P-glycoprotein. Clin. Pharmacokinet. 2001, 40 (3), 159-168.
249. Dresser, G.K.; Spence, J.D.; Bailey, D.O. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin. Pharmacokinet. 2000, 38 (1), 41-57.
250. Lan, L.-B.; Dalton, T.; Schuetz, E.G. Mdr1 limits CYP3A metabolims in vivo. Mol. Pharmacol. 2000, 58 (4), 863-869.
251. Komatani, H.; Kotani, H.; Hara, Y.; et al. Identification of breast cancer resistance protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with anindolocarbazole structure. Cancer Res. 2001, 61, 2827-2832.
252. Wacher, V.J.; Silverman, J.A.; Zhang, Y.; et al. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J. Pharm. Sci. 1998, 87, 1322-1330.
253. Tanaka, E. In vivo age-related changes in hepatic drug-oxidizing capacity in humans (review). J. Clin. Pharm. Ther. 1998, 23, 247-255.
254. Paintaud, G.; Bechtel, Y.; Brientini, M.P.; et al. Effects of liver diseases on drug metabolism (review). Therapie 1996, 51, 384-389.
255. Wandel, C.; Kim, R.B.; Kajiji, S.; et al. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res. 1999, 59, 3944-3948.
256. Thummel, K.E.; Wilkinson, G.R. In vitro and in vivo drug interactions involving human CYP3A (review). Annu. Rev. Pharmacol. Toxicol. 1998, 38, 389-430.
257. leCluyse, E.L. Pregnan X receptor: molecular basis for species differences in CYP3A induction by xenobiotics. Chem.-Biol. Interact. 2001, 134, 283-289.
258. Lehmann, J.M.; McKee, D.D.; Waston, M.A.; et al. The human orphan nuclear receptor PXR is activate by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest. 1998, 102, 1016-1023.
259. Geick, A.; Eichelbaum, M.; Burk, O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J. Biol. Chem. 2001, 276, 14581-14587.
260. MacLeod, S.L.; Nowell, S.; Massengill, J.; et al. Cancer therapy and polymorphisms of cytochrome P450. Clin. Chem. Lab. Med. 2000, 38 (9), 883-887.
261. Meerum Terwogt, J.H.; Malingré, M.M.; Beijnen, J.H.; et al. Mass balance of paclitaxel (Paxene) in humans after both intravenous and oral administration. Proc. Am. Soc. Clin. Oncol. 1999, 18, 190a.
262. Monsarrat, B.; Royer, I.; Wright, R.; et al. Biotransformation of taxoids by human cytochromes P450: structure-activity relationship. Bull. Cancer 1997, 84 (2), 125-133.
263. Brinkmann, U.; Eichelbaum, M. Polymorphisms in the ABC drug transporter gene MDR1. Pharmacogenomics J. 2001, 1 (1), 59-64.
264. Kerb, R.; Hoffmeyer, S.; Brinkmann, U. Hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MPR2. Pharmacogenomics 2001, 2 (1), 51-64.
265. Lamba, J.K.; Lin, Y.S.; Schuetz, E.G.; et al. Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Deliv. Rev. 2002, 54, 1271-1294.
266. Patterson, L.H.; Murray, G.I. Tumour cytochrome P450 and drug activation. Tumour-selective drug activation. Curr. Pharm. Des. 2002, 8 (15), 1335-1347.
267. Doherty, M.M.; Michael, M. Tumoral drug metabolism, perspectives and therapeutic implications. Curr. Drug Metab. 2003, 4, 131-149.
268. Naguib, B.N.; Kouni el, M.H.; Cha, S. Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res. 1985, 45, 5405-5412.
269. Taguchi, T. Experience with UFT in Japan. Oncology 1997, 11 (10), 30-34.
270. Diasio, R.B. The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology. Oncology 1998, 10 (Suppl. 7), 23-27.
271. Schilsky, R.L. Pharmacology and clinical status of capecitabine. Oncology 2000, 14 (9), 1297- 306.
272. Reigner, B.; Blesh, K.; Weidekamm, E. Clinical pharmacokinetics of capecitabine. Clin. Pharmacokinet. 2001, 40 (2), 85-104.
273. Dix, S.P.; Wingard, J.R.; Mullins, R.E.; et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant. 1996, 2, 225-230.
274. van Asperen, J.; van Tellingen, O.; Sparreboom, A.; et al. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br. J. Cancer 1997, 76, 1181-1183.
275. van Asperen, J.; van Tellingen, O.; van der Valk, M.A.; et al. Enhanced oral absorption and decrease elimination of paclitaxel in mice with cyclosporin A. Clin. Cancer Res. 1998, 4, 2293-2297.
276. Sparreboom, A.; van Asperen, J.; Mayer, U.; et al. Limited oral bioavailability and active epithelial excretion of paclitaxel causes by p-glycoprotein in the intestine. Proc. Natl. Acad. Sci. U. S. A. 1997, 24, 2031-2035.
277. Huizing, M.T.; Giaccone, G.; Van Warmerdam, L.J.C.; et al. Pharmacokinetics of paclitaxel and carboplatin in a dose escalating and sequencing study in patients with non-small cell lung cancer: a European Cancer Centre (ECC) trial. J. Clin. Oncol. 1997, 15, 317-329.
278. Malingre, M.M.; Meerum Terwogt, J.M.; Beijnen, J.H.; et al. A phase I and pharmacokinetic study of oral paclitaxel. J. Clin. Oncol. 2000, 18, 2468-2475.
279. Malingre, M.M.; Meerum Terwogt, J.M.; Beijnen, J.H.; et al. Clinical pharmacology of oral paclitaxel in a dose-escalating study. Proc. Am. Soc. Clin. Oncol. 1999, 18, 166a (abstract).
280. van Tellingen, O.; Huizing, M.T.; Nannan Panday, V.R.; et al. Cremophor EL causes (pseudo)nonlinear pharmacokinetics of paclitaxel in patients. Br. J. Cancer 1999, 81, 330-335.
281. Bardelmeijer, H.A.; Ouwehand, M.; Malingre, M.M.; et al. Entrapment by cremophor EL decreases the absorption of paclitaxel from the gut. Cancer Chemother. Pharmacol. 2002, 49, 119- 125.
282. Baas, P.; Mezger, J.; Scheulen, M.E.; et al. In A Phase II Study of Weekly Oral Paclitaxel (Paxoral R) with Cyclosporin A (CsA) for Advanced-Non-Small Cell Lung Cancer (NSCLC), AACR-NCI-EORTC, International Conference; 2001444.
283. Socinski, M.A. Single agent paclitaxel in the treatment of advanced non-small cell lung cancer. Oncologist 1999, 4, 408-416.
284. Kruijtzer, C.M.F.; Schellens, J.H.M.; Mezger, J.; et al. A phase II and pharmacological study of weekly oral paclitaxel (paxoral R) plus cyclosporin A (CsA) in patients with advanced non-small lung cancer (NSCLC). J. Clin. Oncol. 2002, 20, 4508-4510.
285. Kruijtzer, C.M.; Boot, H.; Beijnen, J.H.; et al. Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer. Ann. Oncol. 2003, 2, 175-177.
286. Kruijtzer, C.M.F.; Beijnen, J.H.; Sandman, M.; et al. Oral paclitaxel after prior anthracycline containing chemotherapy in patients with metastatic breast cancer. An interim analysis. In Thesis Kruijtzer CMF; University Utrecht: Ponsen and Looijen, Amsterdam, 2002.
287. Malingré, M.M.; Beijnen, J.H.; Rosing, H.; et al. Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. Br. J. Cancer 2001, 84 (1), 42-47.
288. Bardelmeijer, H.A.; Ouwehand, M.; Beijnen, J.H.; et al. Efficacy of six different P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice. In Thesis Bardelmeijer, University Utrecht: Ponsen and Looijen, Amsterdam, 2002.
289. Marre, F.; Sanderink, G.J.; Desousa, G.; et al. Hepatic biotransformation of docetaxel (taxotere) in vitro: involvement of the CYP3A subfamily in humans. J. Clin. Oncol. 2001, 19, 1160-1166.
290. Malingré, M.M.; Richel, D.J.; Beijnen, J.H.; et al. Co-administration of cyclosporin A strongly enhances the oral bioavailability of docetaxel. J. Clin. Oncol. 2001, 19, 1160-1166.
291. Kruijtzer, C.M.F.; Beijnen, J.H.; Rosing, H.; et al. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein (BCRP) and P-glycoprotein (P-gp) inhibitor GF120918. J. Clin. Oncol. 2002, 20, 2943-2950.
292. Kruijtzer, C.M.F.; Verweij, J.; Schellens, J.H.M.; et al. Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer. Results of a compassionate use program in The Netherlands. Anti-cancer Drugs 2000, 11, 249-255.
293. Kruijtzer, C.M.F.; Malingré, M.M.; Schornagel, J.H.; et al. Activity and toxicity of weekly oral docetaxel plus cyclosporin A in patients with metastatic breast cancer. Results of a phase II study. In Thesis Kruijtzer CMF; Clinical evaluation of novel strategies for oral chemotherapy, Ponsen and Looijen, Amsterdam, 2002.
294. Lück, H.J.; Donnè, S.; Glaubitz, M.; et al. Phase I study of weekly docetaxel (TaxotereR) in heavily pretreated breast cancer patients. Eur. J. Cancer 1997, 33 (Suppl.), 158.
295. Kuppens, I.E.L.M.; van Maanen, M.J.; Rosing, H.; et al. Oral bioavailability of docetaxel in combination with OC 144-093 (ONT-093). Cancer Chemother. Pharmacol. 2005, 55 (1), 72-78.
296. Bardelmeijer, H.A.; Ouwehand, M.; Buckle, T.; et al. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res. 2003, 62 (1), 6158-6164.
297. Messenger, M.; Krozely, M.; Wagner, J.; et al. Intra and inter-patient variability in etoposide AUC following IV and PO administration. Proc. Am. Soc. Clin. Oncol. 1998, 17, 731 (abstract).
298. Harvey, V.J.; Slevin, M.L.; Joel, S.P.; et al. Variable bioavailability following repeated oral doses of etoposide. Eur. J. Cancer Clin. Oncol. 1985, 21, 1315-1319.
299. Smyth, R.D.; Pfeffer, M.; Scalzo, A.; et al. Bioavailability and pharmacokinetics of etoposide (VP-16). Semin. Oncol. 1985, 12 (Suppl. 2), 48-51.
300. Slevin, M.L.; Joel, S.P.; Whomsley, R.; et al. The effect of dose on the bioavailability of oral etoposide: confirmation of a clinically relevant observation. Cancer Chemother. Pharmacol. 1989, 24, 329-331.
301. Shah, J.C.; Chen, J.R.; Chow, D. Preformulation study of etoposide: identification of physicochemical characteristics responsible for the low and erratic oral bioavailability of etoposide. Pharm. Res. 1989, 6 (5), 408-412.
302. Allen, J.D.; van Dort, S.C.; Buitelaar, M.; et al. Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Res. 2003, 63 (6), 1339-1344.
303. Wijnholds, J.; Evers, R.; van Leusden, M.R.; et al. Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nat. Med. 1997, 3, 1275-1279.
304. Bisogno, G.; Cowie, F.; Boddy, A.; et al. High-dose cyclosporin with etoposide-toxicity and pharmacokinetic interaction in children with solid tumours. Br. J. Cancer 1998, 77 (12), 2304-2309.
305. Lum, B.L.; Kaubisch, S.; Fisher, G.A.; et al. Effect of high-dose cyclosporine on etoposide pharmcodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance. Cancer Chemother. Pharmacol. 2000, 45 (4), 305-311.
306. Keller, R.P.; Altermatt, H.J.; Donatsch, P.; et al. Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity. Int. J. Cancer 1992, 51, 433-438.
307. Kobayashi, K.; Ratain, M.J.; Fleming, G.F.; et al. A phase I study of CYP3A4 modulation of oral etoposide with ketoconazol in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol. 1996, 15, 471.
308. Shepard, D.R.; Kobayashi, K.; Wang, C.; et al. Population pharmacokinetic determination of the modulation of oral etoposide (VP-16) elimination by ketoconazol. Proc. Am. Soc. Clin. Oncol. 1998, 732, (abstract).
309. Reif, S.; Nicolson, M.C.; Bisset, D.; et al. Effect of grapefruit juice intake on etoposide bioavailability. Eur. J. Clin. Pharmacol. 2002, 7, 491-494.
310. Doherty, M.M.; Charman, W.N. The mucosa of the small intestine. How clinically relevant as an organ of drug metabolism? Clin. Pharmacol. 2002, 41 (4), 235-253.
311. Schellens, J.H.M.; Creemers, G.J.; Beijnen, J.H.; et al. Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase inhibitor. Br. J. Cancer 1996, 73, 1268-1271.
312. Kuhn, J.; Rizzo, J.; Eckhardt, J.; et al. Phase I bioavailability study of oral topotecan. Proc. Am. Soc. Clin. Oncol. 1995, 14, 474.
313. Jonker, J.W.; Smit, J.W.; Brinkhuis, R.F.; et al. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J. Natl. Cancer Inst. 2000, 92, 1651-1656.
314. Kuppens, I.E.L.M.; Rosing, H.; Stokvis, E.; et al. A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) in combination with 2.0 mg oral topotecan in cancer patients. Br. J. Pharmacol., submitted.
315. Chester, J.D.; Joel, S.P.; Cheeseman, S.L.; et al. Phase 1 and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fluorouracil-refractory metastatic colon cancer. J. Clin. Oncol. 2003, 21 (6), 1125-1132.
316. Kehrer, D.F.S.; Mathijsen, R.H.J.; Verweij, J.; et al. A modulation of irinotecan metabolism by ketoconazole. J. Clin. Oncol. 2002, 20 (14), 3122-3129.
317. Ehrlichman, C.; Boerner, S.A.; Hallgren, C.G.; et al. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer protein-mediated drug efflux. Cancer Res. 2001, 61, 739-748.
318. Nakatomi, K.; Yoshikawa, M.; Oka, M.; et al. Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. Biochem. Biophys. Res. Commun. 2001, 288 (4), 827-832.
319. Luo, F.R.; Paranjpe, P.V.; Guo, A.; et al. Intestinal transport of irinotecan in Caco-2 cells and MDCKII cells overexpressing efflux transporters POP, CMOAT, and MRP1. Drug Metab. Dispos. 2002, 30 (7), 763-770.
320. Marty, M.; Fumoleau, P.; Adenis, A.; et al. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann. Oncol. 2001, 11, 1643-1649.
321. Lucas, S.; Donehower, R.C.; Rowinsky, E.K.; et al. In Absolute Bioavailability (ABA) and Pharmacokinetics of Weekly Navelbine (NVB) Liquid Filled Soft Gelatin Capsules at Full Therapeutic Doses in Patients (pts) with Solid Tumors, Proc. 7th NIC-EORTC Symposium on New Drugs in Cancer Therapy Abstract 264, March 17-20, 1992.
322. Zhou, X.J.; Zhou-Pan, X.R.; Favre, R.; et al. Relative bioavailability of two oral formulations of navelbine in cancer patients. Drug Dispos. 1994, 15, 577-586.
323. Ueda, K.; Cardarelli, C.; Gottesman, M.M.; et al. Expression of full-length DNA for the human MDR1 gene confers resistance to colchicine, doxorubicin and vinblastine. Proc. Natl. Acad. Sci. U. S. A. 1987, 84, 30004-30008.
324. Meyers, M.B.; Scotto, K.W.; Sirotnak, P.M. P-glycoprotein content and mediation of vincristine efflux: correlation with the level of differentiation in luminal epithelium of mouse small intestine. Cancer Commun. 1991, 5, 159-165.
325. Horio, M.; Gottesman, M.M.; Pastan, I. ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells. Natl. Acad. Sci. U. S. A. 1988, 85, 3580-3584.
326. Fojo, A.T.; Akiyama, S.; Gottesman, M.M.; et al. Reduced drug accumulation in multiply drug-resistant cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines. Cancer Chemother. Pharmacol. 1997, 40, 430-438.
327. Litman, T.; Druley, T.E.; Stein, W.D.; et al. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance (review). Cell. Mol. Life Sci. 2001, 58, 931-959.
328. van Asperen, J.; Schinkel, A.H.; Beijnen, J.H.; et al. Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient mice. J. Natl. Cancer Inst. 1996, 88, 994-999.
329. van Tellingen, O.; Buckle, T.; Jonker, J.W.; et al. P-glycoprotein and Mrp1 collectively protect the bone marrow from vincristine-induced toxicity in vivo. Br. J. Cancer 2003, 89 (9), 1776-1782.
330. Rubin, E.H.; de Alwis, O.P.; Pouliquen, I.; et al. A phase I trial of a potent P-glycoprotein inhibitor, zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies. Clin. Cancer Res. 2002, 8 (12), 3710-3717.
331. Callies, S.; Alwis de, P.D.; Harris, A.; Vasey, P.; Beijnen, J.H.; Schellens, J.H.; Burgess, M.; Aarons, L. A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979). Br. J. Clin. Pharmacol. 2003, 56, 46-56.
332. Sparreboom, A.; Planting, A.S.; Jewell, R.C.; et al. Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein. Anti-cancer Drugs 1999, 10, 719-728.
333. Ferry, D.; Price, L.; Atsmon, J.; et al. A phase HA pharmacokinetic and pharmacodynamic study of the P-glycoprotein inhibitor, XR9576 in patients with doxorubicin chemotherapy. Proc. Am. Soc. Clin. Oncol. 2001, 42, 950.
334. Callies, S.; de Alwis, O.P.; Wright, J.G.; et al. A population pharmacokinetic model for doxorubicin and doxorubucinol in the presence of a novel MDR modulator. Zosuquidar trihydrochloride (LY335979). Cancer Chemother. Pharmacol. 2003, 51 (2), 108-118.
335. Lorico, A.; Rappa, G.; Flavell, R.A.; et al. Double knockout of the MRP gene leads to increased drug sensitivity in vitro. Cancer Res. 1996, 56, 5351-5355.
336. Zhang, D.W.; Cole, S.P.; Deeley, R.G. Identification of a nonconserved amino acid residue in multidrug resistance protein 1 important for determining substrate specificity, evidence for functional interaction between transmembrane helices 14 and 17. J. Biol. Chem. 2001, 276, 34966-34974.
337. Smith, D.B.; Margison, J.M.; Lucas, S.B.; et al. Clinical pharmacology of oral and intravenous 4-demethoxydaunorubicin. Cancer Chemother. Pharmacol. 1987, 19, 138-142.
338. Camaggi, C.M.; Strocchi, E.; Carisi, P.; et al. Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study. Cancer Chemother. Pharmacol. 1992, 30, 307-316.
339. Schleyer, E.; Kuhn, S.; Ruhrs, H.; et al. Oral idarubicin pharmacokinetics-correlation of trough level with idarubicin area under curve. Leukemia 1996, 10, 707-712.
340. Hargrave, R.M.; Davey, M.W.; Davey, R.A.; et al. Development of drug resistance is reduced with idarubicin relative to other anthracyclines. Anti-cancer Drugs 1995, 6, 432-437.
341. Berman, E.; McBride, M. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 1992, 79, 119-126.
342. Michieli, M.; Damiani, D.; Michelutti, A.; et al. P 170-dependent multidrug-resistance. Restoring full sensitivity to idarubicin with verapamil and cyclosporin A derivatives. Haematologica 1994, 79, 119-126.
343. Bogush, T.; Robert, J. Comparative evaluation of the intracellular accumulation and DNA binding of idarubicin and duanorubicin in sensitive and multidrug-resistant human leukemia K562 cells. Anticancer Res. 1996, 16, 365-368.
344. Smeets, M.E.P.; Raymakers, R.A.P.; Vierwinden, G.; et al. Idarubicin intercalation is reduced by MRP1 and not Pgp. Leukemia 1999, 13, 1390-1398.
345. Pea, F.; Damiani, D.; Michieli, M.; et al. Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukaemia. Eur. J. Clin. Pharmacol. 1999, 5, 361-368.
346. Larsen, A.K.; Gilbert, C.; Chyzak, G.; et al. Unusual potency of BN 80915, a novel fluorinated E-ring modified camptothecin, toward human colon carcinoma cells. Cancer Res. 2001, 61, 2961-2967.
347. Gridelli, C.; Rossi, A.; Guerriero, C.; et al. Oral cytotoxic drugs. New cytotoxic drugs. Tumori 2002 (Suppl. 4), S19-S23.
348. O'Neill, V.J.; Twelves, C.J. Oral cancer treatment: developments in chemotherapy and beyond. Br. J. Cancer 2002, 87, 933-937.